




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
Macrolides,Lincomycins&PolypeptidesAntibioticsCase1A22monthsoldbabyboycaughtcold5daysago,withfeverandcough.Panting(氣促)2days.Treatedwithpenicillinfor3daysatlocalhospitalbutfailed.PE:T38.5℃,R60/min,P160/min,moistrales(濕羅音)soundatbothlungs.LabtestshownIgMantibody(+)ofmycoplasmapneumoniae(肺炎支原體)Diagnosis:mycoplasmapneumoniaDrugswithspecializedIndicationMacrolides(Erythromycins)ClindamycinPolypeptideantibiotics§1Macrolides(大環(huán)內(nèi)酯類)Theyareagroupofcloselyrelatedcompoundscharacterizedbyamacrocycliclactonering(usuallycontaining14,15or16atoms)towhichdeoxysugars(脫氧糖)areattached.In1950thefirstdrugofthisclasswasisolated:Picromycin(苦霉素)In1952Erythromycin(紅霉素)andCarbomycin(碳霉素)wereintroducedintoclinic.Macrolidesarestableinaqueoussolutionsatorbelowroomtemperature.Theyareunstableinacidicorbasicconditionsorathightemperatures.GoodforG+,G-cocciinfectionHavepostantibioticeffect(PAE)MacrolidesClassification14-atomlactonering:erythromycin(紅霉素),oleandomycin(竹桃霉素),clarithromycin(克拉霉素),roxithromycin(羅紅霉素),dirithromycin(地紅霉素)15-atomlactoneringazithromycin(阿齊霉素semisythetic)16-atomlactoneringmedecamycin(麥迪霉素),acetylmedecamycin(乙酰麥迪霉素),kitasamycin(吉他霉素),acetylkitasamycin(乙酰吉他霉素),josamycin(交沙霉素),spiramycin(螺旋霉素),acetylspiramycin(乙酰螺旋霉素),rokitamycin(羅他霉素)PharmacokineticsofMacrolidesabsorption:Erythromycinbaseisdestroyedbystomachacidandmustbeadministeredwithentericcoating(腸衣).Foodinterfereswithabsorption.Stearates(硬脂酸鹽)andestersarefairlyacid-resistantandbetterabsorbed.Thelaurylsalt(月桂鹽)ofthepropionylester(丙酰脂)oferythromycinisthebest-absorbedoralpreparation.distribution:Absorbeddrugisdistributedwidelyexcepttothebrainandcerebrospinalfluid.ErythromycinistakenupbyWBCandmacrophages.Itreachesthefetus(胎兒).metabolism&excretion:metabolizedinliver,excretedinthebileandlostinfeces,andonly5%isexcretedintheurine.Theserumhalf-lifeisapproximately1.5hnormallyand5hoursinpatientswithanuria.Pharmacodynamicsof
Macrolides1.Antibacterialspectrum:narrow,G+pneumococci,streptococci,staphylococci,corynebacteria(棒狀桿菌);legionella(軍團(tuán)菌),chlamydiahelicobacter,certainmycobacteria(分支桿菌),G-neisseriaspecies(奈瑟菌屬),bordetallapertussis(百日咳)andcampylobacterspecies(彎曲桿菌).somerickettsiaspecies(立克次體),mycoplasma(支原體),trachomatis(衣原體),2.AntibacterialactivityInhibitoryorbactericidal,particularlyathigherconcentrations,forsusceptibleorganisms.ActivityisenhancedatalkalinepH.3.MechanismofantibioticactionInhibitionofproteinsynthesisoccursviabindingtothe50SribosomalRNA.Proteinsynthesisisinhibitedbecauseaminoacyl(氨酰基)translocationreactionsandtheformationofinitiationcomplexesareblocked.ResistancetoMacrolidesUsuallyplasmid-encoded(質(zhì)粒編碼).Threemechanismshavebeenidentified.Modificationoftheribosomalbindingsite;Production(byenterobacteriaceae)ofesterasesthathydrolyzemacrolides;Reducedpermeabilityofthecellmembraneoractiveefflux;Macrolidesthatarecommonlyused
Erythromycin(紅霉素)Clarithromycin(克拉霉素)Azithromycin(阿齊霉素)Roxithromycin(羅紅霉素)Medecamycin(麥迪霉素)Spiramycin(螺旋霉素)Josamycin(交沙霉素)ClinicalusesofErythromycinItisthedrugofchoiceininfectionsdiphtheria,(白喉);inrespiratory,neonatalocularinflammation,orgenital(生殖)chlamydial(衣原體)infections;andintreatmentofcommunity-acquiredpneumoniabecauseitsspectrumofactivityincludesthepneumococcus,mycoplasma(支原體),andlegionella(軍團(tuán)菌).Erythromycinisalsousefulasapenicillinsubstituteinpenicillin-allergicindividualswithinfectionscausedbystaphylococci(assumingthattheisolateissusceptible),streptococci,orpneumococci.Ithasbeenrecommendedasprophylaxisagainstendocarditisduringdentalproceduresinindividualswithvalvularheartdisease.AdversereactionsofErythromycina.GastrointestinaleffectsAnorexia,nausea,vomiting,anddiarrhea.Gastrointestinalintolerance,whichisduetoadirectstimulationofgutmotility,b.LivertoxicityErythromycin,particularlytheestolate,canproduceacutecholestatichepatitis(fever,jaundice,impairedliverfunction),probablyasahypersensitivityreaction.Mostpatientsrecoverfromthis,buthepatitisrecursifthedrugisreadministered.Otherallergicreactionsincludefever,eosinophilia,andrashes.c.DruginteractionsErythromycinmetabolitescaninhibitcytochromeP450enzymesandthus↑theserumconcentrationsofnumerousdrugs,includingtheophylline,oralanticoagulants,cyclosporine,andmehtylprednisolone.Erythromycin↑serumconcentrationsoforaldigoxinby↑itsF.Clarithromycin(克拉霉素)Moreacidstability,moreactivethanerythromycinAgainstToxoplasmagondii(弓形蟲),lowerfrequencyofGIintolerance.Itismetabolizedintheliver.Themajormetaboliteis14-hydroxyclarithromycin,whichhasantibacterialactivity.Allofthemareeliminatedintheurine.Dosage↓forpatientswithrenaldysfunction.Azithromycin(阿齊霉素)A15-atomlactonemacrolide,isactiveagainstTgondii.AzithromycinisslightlylessactivethanerythromycinagainststaphylococciandstreptococciandslightlymoreactiveagainstHinfluenzae.Itishighlyactiveagainstchlamydia(衣原體).Itdiffersfromerythromycinmainlyinpharmacokineticproperties.Itpenetratesintomosttissues,andphagocyticcellsextremelywell,withtissueconcentrationsexceedingserumconcentrationsby10-to100-fold.Drugisslowlyreleasedfromtissuestoproduceaneliminationhalf-lifeapproaching3days.Itisrapidlyabsorbedandwelltoleratedorally.Itshouldbeadministered1hbeforeor2haftermeals.ItdoesnotinactivatecytochromeP450enzymesandisfreeofthedruginteractionsthatoccurwitherythromycin.§2Clindamycins(克林霉素)ClindamycinSincludeLincomycin(林可霉素,潔霉素)Clindamycin(氯林可霉素,氯潔霉素)PharmacokineticsofClindamycin1.Wellabsorbedorally,oriv,about90%protein-bound,highconcentrationinbonetissuse.excretionismainlyviatheliver,bile,andurine.Clindamycinpenetrateswellintomosttissues,itpenetrateswellintoabscesses(膿腫)andisactivelytakenupandconcentratedbyphagocytic(吞噬)cells.2.Itismetabolizedbytheliver,andbothactivedrugandactivemetabolitesareexcretedinbile.Thehalf-lifeisabout2.5hoursinnormalindividuals,increasingto6hoursinpatientswithanuria.Nodosageadjustmentisrequiredforrenalfailure.
pharmacodynemics:
Likeerythromycin,clindamycininhibitsproteinsynthesisbyinterferingwiththeformationofinitiationcomplexesandwithaminoacyltranslocationreactions.Thebindingsiteforclindamycinonthe50Ssubunitofthebacterialribosomeissameasthatforerythromycin.Streptococci,staphylococci,andpneumococciareinhibitedbyclindamycin.EnterococciandG-aerobicorganismsareresistant.Otheranaerobes,bothG+&G-,areusuallysusceptible.
Resistancetoclindamycin
whichgenerallyconferscross-resistancetoothermacrolides,isdueto①mutationoftheribosomalreceptorsite;②modificationofthereceptorbyaconstitutivelyexpressedmethylase;③enzymaticinactivationofclindamycin.ClinicalusesofClindamycin1.Themostimportantindicationforclindamycinisthetreatmentofsevereanaerobicinfection(厭氧菌感染)causedbybacteroidesandotheranaerobesthatoftenparticipateinmixedinfections,especiallybone(骨)infection.2.Incombinationwithanaminoglycosideorcephalosporinisusedtotreatpenetratingwoundsoftheabdomenandthegut;infectionsoriginatinginthefemalegenitaltract,suchassepticabortion(膿毒性流產(chǎn))andpelvicabscesses(盆腔膿腫);oraspirationpneumonia(吸入性肺炎).AdverseeffectsofClindamycinDiarrhea,nausea,andskinrashesarecommonly.Impairedliverfunctionwithorwithoutjaundiceandneutropeniasometimesoccur.§3PolypeptideantibioticsVancomycinsPolymyxinsBacitracinI.VancomycinsincludeVancomycin(萬古)Norvancomycin(去甲萬古)Teicoplanin(替考拉寧)VancomycinisactiveonlyagainstG+bacteria,particularlystaphylococci,aglycopeptideofmolecularweight1500,water-solubleandquitestable.ItinhibitscellwallsynthesisbybindingfirmlytotheD-Ala-D-Alatreminusofnascentpeptidoglycanpentapeptide.Thisinhibitsthetransglycosylase(PBPs),preventingfurtherelongationofpeptidoglycanandcross-linking.Thepeptidoglycanisthusweakenedandthecellbecomessusceptibletolysis.Thecellmembraneisalsodamaged,whichcontributestotheantibacterialeffect.VancomycinisbactericidalforG+bacteria.Mostpathogenicstaphylococci,includingthoseproducing
-lactamaseandthoseresistanttonafcillinandmethicillin,arekilled.ItissynergisticwithgentamicinandstreptomycinagainstEfaecium(糞腸球菌)andEfaecelisstrains.
ResistancetovancomycinisduetomodificationoftheD-Ala-D-AlabindingsiteofthepeptidoglycanbuildingblockinwhichtheterminalD-AlaisreplacedbyD-lactate.Thisresultsinthelossofacriticalhydrogenbondthatfacilitateshigh-affinitybindingofvancomycintoitstargetandlossofactivity.PharmacokineticsofVancomycinPoorlyabsorbedfromtheGItractandisgivenorallyonlyforthetreatmentofantibiotic-associatedenterocolitiscausedbyClostridiumdifficile.widelydistributedinthebody,&passesintothecerebrospinalfluidifthereismeningealinflammation.90%ofthedrugisexcretedbyglomerularfiltration,inrenalinsufficiency,strikingaccumulation.Thedrugisnotremovedbyhemodialysis.ClinicalusesofVancomycinThemainindicationforparenteralvancomycinissepsisorendocarditiscausedbymethicillin-resistantstaphylococci(MRSA).Incombinationwithgentamicinisanalternativeregimenfortreatmentofenterococcalendocarditisinapatientwithseriouspenicillinallergy.Incombinationwithcefotaxime,ceftriaxone,orrifampinfortreatmentofmeningitissuspectedorknowntobecausedbyahighlypenicillin-resistantstrainofpneumococcus.Oralvancomycinisusedtotreatantibiotic-associatedenterocolitiscausedbyClostridiumdifficile.ADRofVancomycinOtotoxicityandnephrotoxicityareuncommonandmildwithcurrentpreparations.Amongthemorecommonreactionsistheso-called“redman”or“redneck”syndrome.Itiscausedbyreleaseofhistamine.Mostadversereactionsareminor.Phlebitis(靜脈炎)atthesiteofinjection.II.Polymyxins(多粘菌素)PolymyxinsareagroupofbasicpeptidesactiveagainstG-bacteria.Owingtotheirnephrotoxicity,allbutpolymyxinsBandEhavebeenabandoned.Theyarecationic,basicpeptideswithmolecularweightsofabout1400.allcontainthefattyacidD-6-methyloctan-1-oicacidandtheaminoacidsL-threonineandL-diaminobutyricacid.PolymyxinsTheyarebactericidalformanyG-rods,includingPseudomonas.Narrowspectrum,sloweffect.Polymyxinsactlikecationicdetergents.Theyattachtoanddisruptbacterialcellmembranes.Theyalsobindandinactivateendotoxin.G+organismsareresistant.Insusceptiblebacterialpopulations,resistantmutantsarerare.Polymyxinsarerarelyusedforsystemicadministrationbecauseoftheirpoortissuedistributionandtheirsubstantialnephrotoxicityandneu
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 勞務(wù)合同范本首
- 借用賬戶走賬合同范本
- 廠房分開幾樓出租合同范本
- 大學(xué)籃球教學(xué)中人文素質(zhì)教育的滲透分析
- 公司出資買房合同范本
- 在古詩文教學(xué)中舒展學(xué)生生命靈性
- 印刷加工銷售合同范本
- 2025年黑龍江省安全員B證(項(xiàng)目經(jīng)理)考試題庫
- 出口窗簾訂單合同范本
- 樂隊(duì)授課服務(wù)合同范本
- H3C-CAS虛擬化平臺(tái)詳細(xì)介紹
- 小學(xué)生韻母in、ing常見漢字與區(qū)分練習(xí)
- 藥房品種類別及數(shù)量清單
- 機(jī)關(guān)檔案管理工作培訓(xùn)PPT課件
- 初中物理人教版八年級(jí)下冊(cè) 第1節(jié)牛頓第一定律 課件
- 網(wǎng)站培訓(xùn)內(nèi)容trswcm65表單選件用戶手冊(cè)
- 連續(xù)平壓熱壓機(jī) 三篇 俞敏等
- 空調(diào)系統(tǒng)維保記錄表格模板
- 打印版-圓與二次函數(shù)綜合題精練(帶答案)
- 各種閥門CAD圖
- 工程結(jié)算書標(biāo)準(zhǔn)
評(píng)論
0/150
提交評(píng)論